William Blair & Company’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$79.2K Hold
1,000
﹤0.01% 1633
2025
Q4
$82.2K Hold
1,000
﹤0.01% 1599
2025
Q3
$69.9K Buy
1,000
+600
+150% +$40.5K ﹤0.01% 1601
2025
Q2
$25.6K Hold
400
﹤0.01% 1660
2025
Q1
$25.4K Hold
400
﹤0.01% 1645
2024
Q4
$26.6K Hold
400
﹤0.01% 1670
2024
Q3
$27.9K Hold
400
﹤0.01% 1683
2024
Q2
$25.9K Hold
400
﹤0.01% 1667
2024
Q1
$25.9K Hold
400
﹤0.01% 1659
2023
Q4
$26.3K Hold
400
﹤0.01% 1648
2023
Q3
$22.8K Hold
400
﹤0.01% 1672
2023
Q2
$24.5K Hold
400
﹤0.01% 1676
2023
Q1
$25.1K Hold
400
﹤0.01% 1666
2022
Q4
$25.4K Hold
400
﹤0.01% 1657
2022
Q3
$24K Hold
400
﹤0.01% 1681
2022
Q2
$23K Hold
400
﹤0.01% 1712
2022
Q1
$25K Hold
400
﹤0.01% 1774
2021
Q4
$28K Hold
400
﹤0.01% 1825
2021
Q3
$30K Hold
400
﹤0.01% 1737
2021
Q2
$31K Hold
400
﹤0.01% 1744
2021
Q1
$30K Hold
400
﹤0.01% 1719
2020
Q4
$28K Hold
400
﹤0.01% 1676
2020
Q3
$23K Hold
400
﹤0.01% 1571
2020
Q2
$23K Hold
400
﹤0.01% 1525
2020
Q1
$19K Hold
400
﹤0.01% 1499
2019
Q4
$22K Hold
400
﹤0.01% 1575
2019
Q3
$19K Hold
400
﹤0.01% 1553
2019
Q2
$21K Hold
400
﹤0.01% 1581
2019
Q1
$22K Hold
400
﹤0.01% 1554
2018
Q4
$19K Hold
400
﹤0.01% 1497
2018
Q3
$24K Hold
400
﹤0.01% 1515
2018
Q2
$22K Hold
400
﹤0.01% 1491
2018
Q1
$20K Buy
+400
New +$20.4K ﹤0.01% 1421

Other funds holding PBE

William Blair & Company's PBE Position: Q1 2026 in Review

William Blair & Company held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2026 at 1,000 shares worth $79.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1633.

William Blair & Company first reported a position in PBE in Q1 2018 and has held it in 33 quarters since. The position peaked at $82.2K in Q4 2025. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

  • William Blair & Company held 1,000 shares of Invesco Biotechnology & Genome ETF worth $79.2K as of Q1 2026.
  • William Blair & Company left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2026.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1633 holding.
  • William Blair & Company first reported a position in Invesco Biotechnology & Genome ETF in Q1 2018 and has held it in 33 quarters since.
  • William Blair & Company's Invesco Biotechnology & Genome ETF position peaked at $82.2K in Q4 2025.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.